At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 186 enrolled
Drug / intervention
Gefitinib +1 moredrug
Likely dose
Gefitinib 250 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multicenter, Randomized, Phase Ib/IIb Study to Evaluate the Efficacy and Tolerability of Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone, in Patients With EGFR Mutation Positive Advanced Non-small-cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating Gefitinib and Olaparib for Non Small Cell Lung Cancer. Completed, enrolled 186 participants across 5 sites.
Detailed Summary
This is a study of gefitinib plus olaparib gefitinib in combination with olaparib (AZD2281) versus gefitinib alone, in patients with Epidermal Growth Factor Receptor (EGFR) mutation positive advanced non-small-cell lung cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small Cell Lung Cancer
CountriesSpain
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2011
First PostedJan 2012
Primary CompletionJul 2016
TodayJul 2026
First PostedJan 20, 2012
Enrollment StartAug 1, 2011
Primary CompletionJul 1, 2016
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 14.5 years ago
Interventions
Gefitinibdrug
Gefitinib 250 mg once a day, continuously, in 28-day cycles, until progression
Olaparibdrug
Gefitinib 250 mg once a day, in combination with olaparib (at the recommended dose in the previous Phase Ib study) twice a day, continuously, in 28-day cycles.